Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Rhea-AI Summary

Scinai Immunotherapeutics (NASDAQ: SCNI) reported first half 2026 results and CDMO business progress. Revenues for the six months ended June 30, 2026 rose to $949 thousand from $773 thousand, driven mainly by the acquired Yavne CDMO operations, while cost of revenues increased to $3.3 million, resulting in a gross loss of $2.4 million.

Operating loss widened to $4.6 million, but net income reached $1.6 million versus a $4.1 million loss a year earlier, primarily due to a $6.4 million bargain purchase gain from the Recipharm Israel acquisition. Cash, cash equivalents and restricted cash totaled about $2.9 million, and shareholders’ equity was $11.7 million. Committed CDMO customer orders were approximately $3.1 million as of August 16, 2026, with roughly $2.1 million invoiced, and about $650 thousand received for an expanded U.S. clinical manufacturing program. Scinai will host an investor webinar on August 26, 2026 at 11:00 a.m. EDT.

Positive

• Revenues increased to $949 thousand from $773 thousand for H1 2026
• Net income of $1.6 million versus a $4.1 million loss in H1 2025
• Recorded a $6.4 million bargain purchase gain from acquiring Recipharm Israel
• Shareholders’ equity rose to $11.7 million from $8.1 million at year-end 2025
• Committed CDMO customer orders reached about $3.1 million as of August 16, 2026
• Approximately $650 thousand cash received for an expanded U.S. clinical manufacturing program

Negative

• Gross loss widened to approximately $2.4 million from $1.3 million in H1 2025
• Operating loss increased to about $4.6 million, up from $3.8 million
• Net cash used in operating activities rose to $3.9 million from $2.6 million
• Cost of revenues grew to $3.3 million versus $2.0 million, exceeding revenue
• Cash, cash equivalents and restricted cash were roughly $2.9 million at June 30, 2026
• Ordinary shares outstanding increased to 22.8 billion from 13.9 billion during 2026

News Explained

First-half securities issuance expanded the share base, reducing existing holders’ percentage ownership absent offsetting changes, while the new customer program remains unsigned.

Scinai says substantive work has begun on an expanded U.S. clinical manufacturing and CMC program, with $650 thousand in payments and advances received, while broader commercial terms remain unsettled.

The company describes the program as supporting a planned U.S. IND submission and Phase III development, but the definitive agreement for the expanded scope is still under negotiation; the disclosure therefore establishes commenced activity, not a completed broader contract.

The specific unresolved item is the definitive agreement covering the broader program's scope and commercial terms, which would clarify the company's contractual commitment and economics.

The first-half statements show June 30, 2026 ordinary shares issued and outstanding of 22,800,887,584, versus 13,872,899,584 at December 31, 2025; the company also recorded issuance of 8,598,960,000 pre-funded warrants, which convert to shares when exercised.

Market Context

Scinai's historical -7.71% response to a comparable earnings update frames this release's operating-...

Analysis

Scinai's historical -7.71% response to a comparable earnings update frames this release's operating-loss and cash-use disclosures. The active F-3 resale registration and low short positioning remained relevant platform context.

Key Figures

Committed customer orders: $3.1 million Invoiced orders: $2.1 million Cash payments and advances: $650 thousand +5 more

8 metrics

Committed customer orders $3.1 million As of August 16, 2026

Invoiced orders $2.1 million Of committed customer orders as of August 16, 2026

Cash payments and advances $650 thousand Expanded U.S. clinical manufacturing program

2026 CDMO revenue pursuit $5 million Company target for 2026

Revenue $949 thousand vs. $773 thousand Six months ended June 30, 2026 vs. 2025

Cost of revenues $3.3 million vs. $2.0 million Six months ended June 30, 2026 vs. 2025

Gross loss $2.4 million vs. $1.3 million Six months ended June 30, 2026 vs. prior-year period

Net income $1.6 million vs. $4.1 million net loss Six months ended June 30, 2026 vs. prior-year period

Historical Context

5 past events · Latest: Aug 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 10	Leadership change	Positive	+2.5%	Appointed supply-chain leader to support CDMO integration and operational scale-up.
Jun 10	Quarterly earnings	Negative	-7.7%	Revenue declined while operating loss widened despite bargain-purchase-driven net income.
May 20	Leadership change	Positive	-6.0%	Named new Yavne site head ahead of planned facility leadership transition.
May 15	Conference participation	Neutral	+0.2%	Led a roundtable on oral therapies and biologics in immunology and dermatology.
Apr 24	Private placement	Negative	+61.6%	Announced $2.61 million financing to expand CDMO operations and fund pipeline programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

SCNI's recent news reactions were mixed, with positive leadership and financing announcements producing both gains and declines.

Key Terms

cdmo, cmc, cgmp

3 terms

cdmo technical

"a revenue-generating contract development and manufacturing organization"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

cmc medical

"expanded clinical manufacturing and CMC program"

Chemistry, Manufacturing, and Controls (CMC) describes the technical documentation and processes that show how a drug or medical product is made, tested for consistent quality, and kept stable from batch to batch. Investors care because strong CMC means a product can be manufactured reliably at scale and meet regulatory standards—similar to proving a recipe can be cooked the same way in any kitchen before restaurants expand—affecting approval, production costs, and potential revenue.

cgmp regulatory

"clinical cGMP manufacturing"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT

JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.

 

 

Corporate Highlights

• Committed Customer Orders¹ reached approximately $3.1 million as of August 16, 2026, of which approximately $2.1 million had been invoiced.
• The Company is progressing an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical company building on an existing contractual relationship and prior work performed through the customer's affiliate.
• Approximately $650 thousand in cash payments and advances have been received in connection with the expanded U.S. program, and substantive activities are underway while the definitive agreement covering the broader scope and commercial terms remains under negotiation.
• The expanded program is intended to support an investigational drug product toward U.S. IND submission and Phase III clinical development.
• The Company continues to pursue approximately $5 million in CDMO revenues for 2026

First Half 2026 Financial Results

• Revenues increased to $949 thousand, compared with $773 thousand for the six months ended June 30, 2025. The increase was primarily attributable to the inclusion of revenues generated by the acquired Yavne operations from the acquisition date. Revenue recognized during the period reflects only the portion of customer engagements for which the applicable services had been performed and revenue recognition criteria satisfied through June 30, 2026, and does not reflect the full value of signed customer work orders extending beyond the reporting period.
• Cost of revenues increased to $3.3 million, compared to approximately $2.0 million for the six months ended June 30, 2025, primarily reflecting the expanded cost base of our CDMO business following the acquisition and consolidation of the Yavne operations, including additional personnel, facility, depreciation and other manufacturing-related costs.
• Gross loss was approximately $2.4 million, compared with approximately $1.3 million in the prior-year period, reflecting the expanded operating cost base of the Company's CDMO platform while facility utilization continues to increase.
• Research and development expenses decreased to approximately $0.8 million, compared to approximately $1.2 million for the six months ended June 30, 2025 primarily reflecting a lower level of research and development expenditures during the period and the continuing allocation of resources toward our CDMO activities, partially offset by expenditures associated with our current therapeutic development programs, including the PinCell arrangement and NanoAb activities. 
• Marketing, general and administrative expenses increased to approximately $1.4 million, compared to approximately $1.3 million for the six months ended June 30, 2025 reflecting, among other things, the expanded corporate and administrative requirements associated with the acquisition and integration of the Yavne operations and operation of the enlarged group structure.
• Operating loss was approximately $4.6 million, compared with approximately $3.8 million for the first half of 2025. 
• Net income was approximately $1.6 million, compared with a net loss of approximately $4.1 million in the prior-year period, primarily reflecting an approximately $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. The bargain purchase gain does not represent operating revenue or operating cash flow. 
• Net cash used in operating activities was approximately $3.9 million, compared with approximately $2.6 million in the first half of 2025. 
• Cash, cash equivalents and restricted cash totaled approximately $2.9 million as of June 30, 2026, and shareholders' equity was approximately $11.7 million. At the closing of the acquisition, Recipharm Israel held approximately €2.0 million in cash, alongside funds for certain pre-closing expenses and liabilities. The acquired cash contributed to the Company's post-acquisition liquidity position.

CEO Commentary

Amir Reichman, Chief Executive Officer of Scinai, commented:

"The first half of 2026 was focused on expanding and integrating our CDMO platform. As we move through the second half of the year, our focus is increasingly on commercial execution, increasing facility utilization and converting the capabilities we have built into revenue.

We are particularly encouraged by the expansion of an existing U.S. customer engagement from an initial feasibility and cGMP-readiness project into a broader proposed clinical manufacturing and CMC program designed to support a planned U.S. IND submission and Phase III clinical development with potential future expansion into commercial manufacturing. We have already received approximately $650 thousand in cash payments and advances and commenced substantive activities while the definitive agreement covering the expanded scope and commercial terms is being negotiated.

We believe this opportunity is significant not only because of its potential financial contribution, but also because successful execution would demonstrate our ability to support an advanced U.S. clinical development program through CMC development, manufacturing readiness and clinical cGMP manufacturing.

Our priorities for the remainder of 2026 are clear: execute our existing customer programs, convert our commercial pipeline into revenue, increase utilization of our Jerusalem and Yavne facilities, progress this significant U.S. opportunity and continue advancing our therapeutic programs with disciplined capital allocation."

R&D Update

Scinai continues to pursue a capital-efficient development strategy focused on PC111 and its NanoAbs platform.

For PC111, the Company is evaluating its funding and development path, including potential participation in a future Polish FENG funding round, and is in discussions with PinCell regarding a potential extension of the existing option arrangement.

For the NanoAbs platform, Scinai continues to prioritize its systemic IL-17 bispecific antibody program and its research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.

Investor Webinar

Scinai will provide additional perspective on the expanded U.S. clinical manufacturing opportunity, its broader CDMO commercial pipeline, progress across its R&D programs, including PC111 and the NanoAbs platform, and its strategic priorities for the remainder of 2026 during an investor webinar on August 26, 2026 at 11:00 a.m. EDT.

Investors and other interested parties are invited to register here: LINK

The webinar will include a management presentation followed by a question-and-answer session.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization.

The Company is advancing therapeutic programs based on technology licensed from the Max Planck Society and pursuant to its option arrangement with PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit www.scinai.com.

Company Contacts

Business Development | +972 8 930 2529 | bd@scinai.com

Investor Relations, Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com

⁽¹⁾ Committed Customer Orders

• We define "committed customer orders" as the aggregate value of signed customer purchase orders for specified CDMO services under existing contractual arrangements, whether or not such amounts have been invoiced. Management uses committed customer orders as an indicator of committed commercial activity and anticipated CDMO utilization, and we believe this measure provides investors with useful information regarding the value of customer-authorized projects under signed purchase orders.
• Committed customer orders are presented for supplemental informational purposes only and are not intended as a substitute for GAAP financial measures. Although customer purchase orders are generally non-cancellable, committed customer orders should not be interpreted as an indication of future revenue or cash receipts. The timing and amount of revenue recognition and cash payments depend on various factors, including performance of the applicable services, achievement of contractual milestones and satisfaction of the relevant accounting criteria. Projects may also be delayed, modified or remain open for extended periods.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the growth of the Company's CDMO business;  Committed Customer Orders; future and expansion of existing customer engagements and business-development opportunities; utilization of the Jerusalem and Yavne facilities.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks that the Company will be unable  to execute customer projects and convert commercial opportunities into recognized revenue and cash flow; that the contemplated expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical company will not be an beneficial to the Company as anticipated, will not occur or will be delayed; that the Company will not successfully negotiate and execute definitive customer agreements; that the Company will not successfully perform development, scale-up and cGMP manufacturing activities; that the Company will not increase facility utilization, attract and retain customers and partners; that the Company will not achieve its revenue targets; that the Company will not successfully advance its PC111 and the NanoAbs platform; that the Company will not succeed in obtaining potential non-dilutive funding from its grant applications; that the Company will be unable to obtain sufficient financing or non-dilutive funding; and that the Company will be unable to regain and maintain compliance with Nasdaq's continued-listing requirements. Additional risks and uncertainties are described in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements.

 

SCINAI IMMUNOTHERAPEUTICS LTD
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
 As of June 30, 2026
 Unaudited

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
	June 30,			December 31,
	2026			2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2,654		$	1,661
Restricted cash		199			150
Prepaid expenses and other receivables		561			170
Trade receivables		74			73
Total current assets		3,488			2,054
NON-CURRENT ASSETS:
Property, plant and equipment, net		10,711			7,793
Operating lease right-of-use assets		2,976			1,779
Total non-current assets		13,687			9,572
Total assets	$	17,175		$	11,626
The accompanying notes are an integral part of the condensed consolidated financial statements.

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share data)
	June 30,			December 31,
	2026			2025
LIABILITIES NET OF CAPITAL DEFICIENCY
CURRENT LIABILITIES:
Trade payables	$	844		$	407
Operating lease liabilities		369			329
Other payables		1,019			849
Total current liabilities		2,232			1,585
NON-CURRENT LIABILITIES:
Loan from others		285			294
Non-current operating lease liabilities		2,926			1,644
Total non-current liabilities		3,211			1,938
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS' EQUITY:
Ordinary shares of no par value: Authorized: 1,600,000,000,000 shares at June 30, 2026 and at December 31, 2025; Issued and outstanding 22,800,887,584, shares at June 30, 2026 and 13,872,899,584 shares at December 31, 2025					-
Preferred shares, no par value; Authorized: 1,000 shares at June 30, 2026 and 1,000 shares at December 31, 2025 (redemption amount of $34,000); Issued and outstanding: 1,000 shares at June 30, 2026 and 1,000 shares at December 31, 2025.		5,627			5,627
Additional paid-in capital		132,516			130,062
Accumulated deficit		(124,272)			(125,846)
Accumulated other comprehensive loss		(2,139)			(1,740)
Total shareholders' equity		11,732			8,103
Total liabilities and shareholders' equity	$	17,175		$	11,626

 

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share data)
	For the six months ended June 30,
	2026				2025
Revenues		949				773
Cost of revenues	$	(3,319)			$	(2,043)
Gross profit (loss)		(2,370)				(1,270)
Research and development expenses, net		(839)				(1,237)
Marketing, general, and administrative expenses		(1,404)				(1,256)
Total operating expenses		(2,243)				(2,493)
Total operating profit (loss)		(4,613)				(3,763)
Gain from bargain purchase		6,401				-
Total Financial Income (Expenses)  net,		(214)				(371)
Net profit (loss)	$	1,574			$	(4,134)
Net loss per share attributable to ordinary shareholders, basic and diluted		(*)				(0.001)
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted		30,189,667,540				6,364,731,650
*Less than $0.01
The accompanying notes are an integral part of the condensed consolidated financial statements.

 

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share data)
		For the six  months ended June 30
		2026				2025
Net profit (loss)	$	1,574			$	(4,134)
Other comprehensive income:
Foreign currency translation adjustments		(399)				-
Total comprehensive profit  (loss)		1,175			$	(4,134)

 

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
U.S. dollars in thousands (except share data)
		Ordinary shares				Preferred shares								Additional						Accumulated				Accumulated				Total
		Number		Amount		Number				Amount					paid-in capital					comprehensive loss				equity (deficit)				shareholders' equity (deficit)
Balance as of January 1, 2026		13,872,899,584			-		1,000			$	5,627						130,062				(1,740)				(125,846)				8,103
Vested RSU's		279,100,000			-		-				-						-				-								-
Share-based compensation		-			-		-				-						128				-								128
Issuance of pre-funded warrants, net of issuance costs		8,598,960,000															2,321												2,321
Cumulative translation adjustment																					(399)								(399)
Issuance of ordinary shares		49,928,000			-		-				-						5				-								5
Net profit (loss)		-			-		-				-						-				-				1,574				1,574
Balance as of June 30, 2026		22,800,887,584			-		1,000				5,627						132,516				(2,139)				(124,272)				11,732
*Ordinary shares have no par value

 

 

		Ordinary shares				Preferred shares								Additional						Accumulated								Total
		Number		Amount		Number				Amount					paid-in capital					comprehensive loss				Accumulated equity (deficit)				shareholders' equity (deficit)
Balance as of January 1, 2025		3,411,983,584			*		1,000			$	5,627					$	123,629			$	(1, 740(	(		$	(117,539 )			$	9,977
Vested RSU's		32,816,000			-		-				-						-				-				-				-
Share-based compensation																	270												270
Exercise of prefunded warrants		322,944,000			-		-				-						-				-				-				-
Issuance of ordinary shares		2,288,880,000			-		-				-					$	1,745				-				-			$	1,745
Net loss		-			-		-				-						-				-				(4,134)				(4,134)
Balance as of June 30, 2025		6,056,623,584			-		1,000			$	5,627					$	125,644			$	(1,740()			$	(121,673)			$	7,858

 

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
		For the six months  ended June 30,
		2026				2025
Cash flows from operating activities:
Net profit (loss)		$	1,574			$	(4,134)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of property, plant and equipment			1,039				704
Financial expense (income) related to loan from others			(9)				33
Share-based compensation			128				270
Decrease (increase)  in trade receivables			129				(56)
Gain from bargain purchase			(6,401)				-
Decrease (increase) in other receivables			(233)				(23)
Effect of exchange rate changes on cash, cash equivalents and restricted cash			(226)				(42)
SEPA commitment fees							164
Changes in operating lease right-of-use assets			117				31
Increase in trade payables			264				283
Changes in operating lease liabilities			(117)				237
Increase (decrease) in other payables			(185)				(42)
Net cash used in operating activities			(3,920)				(2,575)
Cash flows from investing activities:
Purchase of property, plant and equipment			(115)				(12)
Cash received in business combination			2,751				-
Net cash used in investing activities		$	2,636			$	(12)

 

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
		For the six months ended June 30,
		2026				2025
Cash flows from financing activities:
Proceeds from issuance of ordinary shares for SEPA holders, net			5			1,581
Proceeds pre-funded warrants for PIPE holders, net			2,321
Net cash provided by financing activities			2,326			1,581
Effect of exchange rate changes on cash, cash equivalents and restricted cash			-			42
Increase (decrease) in cash, cash equivalents and restricted cash			1,042			(946)
Cash, cash equivalents and restricted cash at beginning of period			1,811			2,095
Cash, cash equivalents and restricted cash at end of period		$	2,853			1,131
Non-cash transactions:
Shares issued for SEPA financing agreement		$	6			100
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents		$	2,654			989
Restricted cash			199			142
Cash, cash equivalents and restricted cash		$	2,853			1,131

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-reports-first-half-2026-corporate-highlights-and-results-with-spotlight-on-growing-cdmo-momentum-302858235.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What were Scinai (NASDAQ: SCNI) key financial results for the first half of 2026?

Scinai reported H1 2026 revenues of $949 thousand and net income of $1.6 million. According to Scinai, higher CDMO activity and a $6.4 million bargain purchase gain from Recipharm Israel offset a $4.6 million operating loss and gross loss of about $2.4 million.

Why did Scinai report net income in H1 2026 after a loss in H1 2025?

Scinai’s H1 2026 net income of $1.6 million mainly reflects a $6.4 million bargain purchase gain. According to Scinai, this non-operating gain from the Recipharm Israel acquisition outweighed a larger operating loss, reversing the prior-year net loss of about $4.1 million.

What is the value of Scinai’s committed CDMO customer orders as of August 16, 2026?

Scinai reported committed CDMO customer orders of approximately $3.1 million as of August 16, 2026. According to Scinai, around $2.1 million of this amount had been invoiced, and committed orders represent signed purchase orders but are not direct indicators of future revenue or cash receipts.

How did the Recipharm Israel acquisition impact Scinai’s H1 2026 results and balance sheet?

The Recipharm Israel acquisition generated a $6.4 million bargain purchase gain and added cash. According to Scinai, Recipharm Israel held about €2.0 million in cash at closing, contributing to liquidity and supporting shareholders’ equity of approximately $11.7 million at June 30, 2026.

What was Scinai’s cash position as of June 30, 2026, and how does it compare to year-end 2025?

Scinai held about $2.9 million in cash, cash equivalents and restricted cash at June 30, 2026. According to Scinai, this compares with roughly $1.8 million at December 31, 2025, following the Recipharm Israel acquisition and increased CDMO-related activities and operating cash usage.

How did Scinai’s operating performance change in H1 2026 versus H1 2025?

Operating loss increased to about $4.6 million in H1 2026 from $3.8 million in H1 2025. According to Scinai, this reflected higher CDMO cost of revenues and expanded corporate expenses, while research and development spending decreased to approximately $0.8 million from about $1.2 million.

When is Scinai’s August 2026 investor webinar and what will it cover for SCNI shareholders?

Scinai scheduled an investor webinar for August 26, 2026 at 11:00 a.m. EDT. According to Scinai, management will discuss the expanded U.S. clinical manufacturing opportunity, the broader CDMO commercial pipeline, progress on PC111 and NanoAbs programs, and strategic priorities for the remainder of 2026.